Perspectives

How does this study impact clinical practice?

• Patients with chronic migraine undergoing treatment with onabotulinumtoxinA can experience a significant further reduction in monthly headache days and pain severity with the addition of a CGRP mAb medication.
• Future prospective studies evaluating combination therapy are warranted.